warfarin and Birth-Weight

warfarin has been researched along with Birth-Weight* in 6 studies

Other Studies

6 other study(ies) available for warfarin and Birth-Weight

ArticleYear
Heart disease in pregnancy: cardiac and obstetric outcomes.
    Archives of gynecology and obstetrics, 2013, Volume: 288, Issue:1

    A retrospective analysis of the records of all the patients of heart disease with pregnancy at AIIMS, New Delhi, India, to find out the maternal and fetal outcome.. A retrospective analysis was carried out of 100 pregnancies in women with heart disease who delivered at ≥28 weeks of gestation from July 2009 through August 2012.. Cardiac disease was found to complicate 3.8 % of pregnancies. Rheumatic heart disease (n = 64, 64 %) was the predominant cardiac disease. Congenital heart disease was found to complicate 36 pregnancies (n = 36, 36 %).Cardiac complications were seen in 32 (32 %) and fetal complications in 18 (18 %) pregnancies. Fewer cardiac and postpartum complications were present in NYHA class I/II patients compared to NYHA III/IV patients (P < 0.05). Pregnancy outcome was better in rheumatic heart disease patients who had undergone cardiac intervention prior to pregnancy (n = 29, 45.2 %) compared to those whose heart disease remained uncorrected (n = 35, 54.8 %) but the difference was not statistically significant. There was one maternal mortality in a patient with Eisenmenger syndrome. Two of the newborns of the 17 women who had received anticoagulants had features of warfarin embryopathy.. Pregnancy in women in NYHA class III/IV is associated with significantly higher maternal morbidity and cardiac interventions before pregnancy, when indicated may improve pregnancy outcome.

    Topics: Adult; Anticoagulants; Aortic Valve; Birth Weight; Female; Fetal Diseases; Fetal Growth Retardation; Heart Defects, Congenital; Heart Valve Diseases; Humans; Mitral Valve; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Retrospective Studies; Rheumatic Heart Disease; Severity of Illness Index; Warfarin; Young Adult

2013
Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study.
    Thrombosis and haemostasis, 2006, Volume: 95, Issue:6

    Vitamin K antagonists (VKA) are known to act as teratogens; however, there is still uncertainty about the relative risk for birth defects and the most sensitive period. In a multi-centre (n = 12), observational, prospective study we compared 666 pregnant women exposed to phenprocoumon (n = 280), acenocoumarol (n = 226), fluindione (n = 99), warfarin (n = 63) and phenindione (n = 2) to a non-exposed control group (n = 1,094). Data were collected by institutes collaborating in the European Network of Teratology Information Services (ENTIS) during individual risk counselling between 1988 and 2004. Main outcome measures were coumarin embryopathy and other birth defects, miscarriage rate, birth-weight, and prematurity. The rate of major birth defects after 1st trimester exposure was significantly increased (OR 3.86, 95% CI 1.86-8.00). However, there were only two coumarin embryopathies (0.6%; both phenprocoumon). Prematurity was more frequent (16.0% vs. 7.6%, OR 2.61, 95% CI 1.76-3.86), mean gestational age at delivery (37.9 vs.39.4, p<0.001), and mean birth weight of term infants (3,166 g vs. 3,411 g; p < 0.001) were lower compared to the controls. Using the methodology of survival analysis, miscarriage rate reached 42% vs. 14% (hazard ratio 3.36; 95% CI 2.28-4.93). In conclusion, use of VKA during pregnancy increases the risk of structural defects and other adverse pregnancy outcomes. The risk for coumarin embryopathy is, however, very small, in particular when therapy during the 1(st) trimester did not take place later than week 8 after the 1(st) day of the last menstrual period. Therefore, elective termination of a wanted pregnancy is not recommended if (inadvertent) exposure took place in early pregnancy. Close follow-up by the obstetrician including level II ultrasound should be recommended in any case of VKA exposure during pregnancy.

    Topics: Abnormalities, Drug-Induced; Abortion, Induced; Abortion, Spontaneous; Acenocoumarol; Adverse Drug Reaction Reporting Systems; Anticoagulants; Birth Weight; Female; Fetal Diseases; Gestational Age; Humans; Phenindione; Phenprocoumon; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Premature Birth; Prospective Studies; Vitamin K; Warfarin

2006
Pregnancy outcome in women with prosthetic heart valves.
    American journal of obstetrics and gynecology, 2004, Volume: 191, Issue:3

    This study was undertaken to evaluate the risks and pregnancy outcome in women with prosthetic heart valves on different anticoagulent regimens.. A retrospective chart review of 82 pregnancies in 33 women with mechanical valve prostheses at a tertiary referral center from 1987 to 2002. The main outcome measures were major maternal complications and perinatal outcome.. The valve replaced was mitral (60.6%), aortic (18.2%), and both (21.2%). Fifty-four pregnancies (65.9%) resulted in live births, 9 (11.0%) had stillbirths (all on warfarin), and 12 (14.6%) had spontaneous and 7 (8.5%) therapeutic abortions (all on warfarin). The rate of spontaneous abortion was highest in women on warfarin throughout pregnancy (P < .01). The live birth rate was higher in women on heparin compared with those on warfarin (P < .01), and in those on heparin/warfarin compared with warfarin alone (P < .01). There were no maternal deaths; however, 3 patients had mitral valve thrombosis (2 on heparin and 1 on warfarin) necessitating surgery in 1 patient and medical thrombolysis in 2 patients. Hemorrhagic complications occurred in 5 patients, 4 of whom required transfusion.. No single anticoagulant regimen confers complete protection from thromboembolic phenomena in pregnancy. Despite a high maternal morbidity rate, the perinatal outcome is acceptable when pregnancy progresses beyond the first trimester.

    Topics: Abortion, Spontaneous; Abortion, Therapeutic; Birth Weight; Delivery, Obstetric; Female; Fetal Death; Fetal Growth Retardation; Gestational Age; Heart Valve Prosthesis; Heparin; Humans; Mitral Valve; Obstetric Labor, Premature; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies; Thrombosis; Vitamin K; Warfarin

2004
[The follow-up of 12 pregnant women with anticoagulation therapy after mechanical heart valve replacement].
    Zhonghua fu chan ke za zhi, 2001, Volume: 36, Issue:8

    The article discusses the effect of warfarin on pregnant women and their fetus, and the methods of anticoagulation therapy during pregnancy.. The pregnancy, delivery, and anticoagulation therapy of 12 pregnant women with mechanical heart valve replacement were followed-up.. All the patients received oral anticoagulant therapy during pregnancy. The mean dose of imported warfarin was (2.71 +/- 1.24) mg/d (4 cases); domestic warfarin, (3.14 +/- 0.28) mg/d (6 cases); domestic acenocumarol tablet (3.14 +/- 1.08) mg/d (2 cases). No thromboembolism and major hemorrhage occurred. A total of 8 person/times had minor bleeding. Ten patients had term delivery, 2 had premature birth, No abnormal fetus was observed. Only 1 newborn had low birth weight (2,100 g).. The anticoagulation therapy with low dosage of warfarin (< 5 mg/d) is safe and convenient for the mothers during pregnancy following mechanical heart valve replacement and has low fetus abnormal rate.

    Topics: Adult; Anticoagulants; Birth Weight; Female; Fetus; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications; Warfarin

2001
Patent foramen ovale as a potential cause of paradoxical embolism in the postpartum period.
    European journal of obstetrics, gynecology, and reproductive biology, 1999, Volume: 84, Issue:1

    We report a case of previously healthy woman who suffered cerebral embolism after delivery. Echocardiography with contrast medium confirmed the patent foramen ovale (PFO). PFO may be a mechanism of paradoxical embolism causing a transient ischemic attack or stroke.

    Topics: Adult; Anticoagulants; Apgar Score; Birth Weight; Echocardiography; Embolism, Paradoxical; Female; Heart Septal Defects, Atrial; Hematocrit; Hemoglobins; Heparin; Humans; Infant, Newborn; Maternal Age; Oligohydramnios; Oxytocin; Postpartum Period; Pregnancy; Pregnancy, High-Risk; Tomography, X-Ray Computed; Warfarin

1999
Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prostheses.
    The American journal of cardiology, 1989, Jun-15, Volume: 63, Issue:20

    Previous reports indicate an increased risk of thrombotic and embolic events in patients with mechanical heart valve prostheses during pregnancy. We prospectively followed 50 pregnancies in 49 patients with 62 cardiac prostheses from presentation at the antenatal clinic through the remainder of the pregnancy. Of the 60 mechanical prostheses, 39 were Medtronic-Hall, 7 St. Jude Medical, 7 Starr-Edwards and 7 Björk-Shiley. Forty-three patients were in New York Heart Association functional class I or II and 6 were in functional class III or IV. Forty-five patients were in sinus rhythm and 4 had chronic atrial fibrillation. All patients received warfarin during the first and second trimesters. Forty-one pregnancies proceeded beyond 28 weeks. In 23 of these (group I) warfarin was replaced with heparin at 36 weeks gestation. In the remaining 18 (group II) warfarin was not substituted owing to premature onset of labor. The target prothrombin ratio (international normalized ratio) in patients receiving warfarin was 2.0 to 2.5. The partial thromboplastin time was maintained at 1.5 to 2.5 times the control value in patients receiving heparin. Eleven patients received dipyridamole plus warfarin for the duration of pregnancy. There were no maternal thromboembolic complications or deaths associated with pregnancy. Antepartum hemorrhage occurred in 1 patient at 35 weeks gestation. One patient (group I) experienced peripartum hemorrhage. All patients were hemodynamically stable before delivery, but 2 developed pulmonary edema during labor. The mean fetal birth weight was low (2.54 +/- 0.98 kg). There were 9 abortions (18%), 7 stillbirths (14%), 2 neonatal deaths (4%) and 2 instances of warfarin embryopathy (4%).(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Adolescent; Adult; Anticoagulants; Birth Weight; Blood Coagulation; Dipyridamole; Female; Fetus; Heart Valve Prosthesis; Heparin; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Prospective Studies; Thrombosis; Warfarin

1989